Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bupivicaine alone · 1 trial · 1 indication
The Pain Disability Index (PDI) measures patients' responses of the extent to which pain limits their abilities to carry out everyday tasks. The index is scored from 0 (no limitation) to 70 (severe limitation). A decrease in score of 10 points or more is regarded as indicating significant improvement in the ability to carry out daily activities.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | EUS guided celiac block with bupivicaine and triamcinolone. Patient will undergo endoscopic ultrasound and celiac plexus blockade using an EUS needle inserted into the celiac plexus. 20 cc of injectate will be administered. |
| 2 | PLACEBO_COMPARATOR | EUS guided celiac block with bupivicaine only. Patient will undergo endoscopic ultrasound and celiac plexus blockade using an EUS needle inserted into the celiac plexus. 20 cc of injectate will be administered. |
| Name | Type | Description |
|---|---|---|
| Triamcinolone | DRUG | Injection of bupivacaine and triamcinolone |
| Bupivicaine alone | DRUG | Injection of bupivacaine |
Inclusion criteria include: * Age \>18 yrs * Ability for informed consent * Chronic pancreatic-type abdominal pain (type B) (11). Exclusion criteria include: * Pregnancy * Malignancy * Recent acute pancreatitis (within 2 months) * Elevated INR (\>1.5) or low platelet count (\<75 cells/mm3) * Alle...
Bupivicaine alone is being studied for the treatment of chronic pancreatitis. It is administered via endoscopic ultrasound-guided celiac plexus blockade to manage pain associated with this condition. The drug is in Phase 3 clinical development and is being evaluated by Community Health Systems, Inc.
Bupivicaine alone is a small molecule that works as a local anesthetic. It blocks nerve signals in the celiac plexus, a network of nerves in the abdomen, to relieve pain in patients with chronic pancreatitis. This mechanism is being tested in a Phase 3 clinical trial.
Bupivicaine alone is being developed by Community Health Systems, Inc., a company traded on the New York Stock Exchange under the ticker symbol CYH. The company is conducting a Phase 3 clinical trial to evaluate the drug for chronic pancreatitis.
Bupivicaine alone is in Phase 3 clinical development for chronic pancreatitis. It is an investigational drug and has not been approved by the FDA. The Phase 3 trial has been completed, with results expected to inform further development.
Bupivicaine alone is associated with one completed Phase 3 clinical trial, NCT00658736, titled 'Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis.' This randomized, double-blind, placebo-controlled trial enrolled 40 participants in the United States and evaluated the drug's efficacy in chronic pancreatitis.
Bupivicaine alone is a form of bupivacaine, a local anesthetic. In the context of this clinical trial, it is used as a single agent for celiac plexus blockade in chronic pancreatitis. The drug is being studied as a standalone treatment, without combination with other agents.